Ungar Leo, Sanders David, Becerra Brian, Barseghian Ailin
Department of Cardiology, University of California, Irvine, Irvine, CA, United States.
Department of Internal Medicine, University of California, Irvine, Irvine, CA, United States.
Front Cardiovasc Med. 2018 Aug 30;5:116. doi: 10.3389/fcvm.2018.00116. eCollection 2018.
Familial hypercholesterolemia (FH) is a common heritable condition in which mutations of genes governing cholesterol metabolism result in elevated LDL levels and accelerated atherosclerosis. The treatment of FH focuses on lipid lowering drugs to decrease patients' cholesterol levels and reduce their risk of cardiovascular events. Even with optimal medical therapy, some FH patients will develop coronary atherosclerosis, suffer myocardial infarction, and require revascularization. Yet, the revascularization of FH patients has not been widely studied. Here we review FH, identify unanswered questions in the interventional management of FH patients, and explore barriers and opportunities for answering these questions. Further research is needed in this neglected but important topic in interventional cardiology.
家族性高胆固醇血症（FH）是一种常见的遗传性疾病，其中控制胆固醇代谢的基因突变会导致低密度脂蛋白（LDL）水平升高和动脉粥样硬化加速。FH的治疗重点是使用降脂药物来降低患者的胆固醇水平，并降低他们发生心血管事件的风险。即使采用最佳药物治疗，一些FH患者仍会发生冠状动脉粥样硬化、心肌梗死，并需要进行血运重建。然而，FH患者的血运重建尚未得到广泛研究。在此，我们对FH进行综述，确定FH患者介入治疗管理中尚未解答的问题，并探讨回答这些问题的障碍和机会。在介入心脏病学这一被忽视但重要的课题上，还需要进一步研究。
